Table 2.
Clinical Data of Patients Who Received Infliximab for Liver Dysfunction Due to ICIs.
| No. | Sex | Age | Cancer | Drugs (cycles) |
Days until onset | Liver biopsy | Peak AST (IU/L) | Peak ALT (IU/L) | Peak T-Bil (mg/dL) | Peak ALP (IU/L) | Peak γ-GTP (IU/L) | Other treatments | Effect of infliximab | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 46 | melanoma | Ipi+Niv (1) | 30 days | No | - | 2,854 | - | - | - | mPLS, PSL, MMF | improve | 7 |
| 2 | F | 53 | melanoma | Ipi+Niv (3) | 81 days | Yes | - | 1,200< | 29< | 857 | - | mPSL, PLS, MMF | improve | 8 |
| present case | M | 69 | NSCLC | Durvalumab (1) | 38 days | No | 385 | 615 | 10.2 | 4,780 | 1,888 | mPSL, PSL, MMF, AZA, tacrolimus | improve |
AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyl transpeptidase, Ipi: ipilimumab, Niv: nivolumab, NSCLC: non-small cell lung cancer, PSL: prednisolone, MMF: mycophenolate mofetil, AZA: azathioprine